Numinus rolls out the list of Advisors on its psychedelics Advisory Council
Exploring the companies and themes that make up this emerging and exciting new sector
Primo Nutraceuticals Inc., Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of Psilocybin Mushrooms
Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.
Heroic Hearts Project and Field Trip Health Ltd. enter into a strategic relationship to increase legal psychedelic therapy access for military veterans in North America
Field Trip's new strategic partnership will facilitate bringing its ketamine-assisted psychotherapy for PTSD to military veterans.
Field Trip Adds Acclaimed Physician, Dr. Andrew Weil, to Medical Advisory Board
Field Trip has appointed a leader in holistic and integrative medicine to its Medical Advisory Board.
MindMed Announces $25 Million Bought Deal Public Offering
MindMed announces a CAD$25 million bought-deal financing at CAD$1.05 per unit.
MindMed Cashes In, $25 Million Bought Deal Financing
MindMed has capitalized on its recent market success to raise new capital on more favorable terms.
Release: Health and Wellness Industry Tastemaker Jon Bier Joins Mind Cure's (CSE: MCUR) Advisory Board
Mr. Bier is a communications and strategy expert who has played a key role in building brands such as Four Sigmatic and WHOOP
Numinus Commences Psilocybe Mushroom Cultivation
Numinus commences psilocybin cultivation as part of its "ecosystem approach" to psychedelic drug therapy.
Mind Cure Assembles Cast For Psychedelic Drug Success
After a series of significant corporate appointments, Mind Cure is poised to advance its operations.
Mind Cure Welcomes Dr. Jason Wallach to Scientific Advisory Board
Mind Cure's latest addition to its Scientific Advisory Board is a noted expert in psychedelic medicine, published researcher, and professor of pharmacology.
Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin
Mydecine's new patent application may lead to a way to derive the medicinal benefits of psilocybin at lower doses.
Upstart Mind Cure (CSE:MCUR) Targets Disrupting $300 Billion Industry
The mental healthcare industry is ripe for innovation. And companies like Mind Cure (CSE: MCUR), which recently completed its IPO, are set to lead the way.